Effectiveness and Safety of P2Y12 Inhibitor Pretreatment for Primary PCI in STEMI: Systematic Review and Meta-analysis

*Cardiology Department, Hospital de Santa Cruz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal; and

†Comprehensive Health Research Centre, NOVA Medical School, Universidade Nova de Lisboa, Lisboa, Portugal.

Correspondence: João Presume, MD, Av. Prof. Dr. Reinaldo dos Santos, 2790-134 Carnaxide, Lisbon, Portugal (e-mail: [email protected]).

J. Ferreira reports consulting fees for Astra Zeneca.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.jcvp.org).

Conception and design: J. Presume, D. Gomes, J. Ferreira, F. Albuquerque, M. Almeida, M. S. Uva, C. Aguiar, M. Mendes; Data collection: J. Presume, D. Gomes; Data analysis: J. Presume, D. Gomes, J. Ferreira; Drafting: J. Presume, D. Gomes, J. Ferreira, F. Albuquerque, M. Almeida, M. S. Uva, C. Aguiar, M. Mendes; Revising: J. Presume, D. Gomes, J. Ferreira, F. Albuquerque, M. Almeida, M. S. Uva, C. Aguiar, M. Mendes All authors read and approved the final manuscript.

This is a study-level meta-analysis. All the data used has been previously published in other studies and is available online.

This article has been published in a pre-print research database which is not indexed in Medline or Pubmed - https://doi.org/10.21203/rs.3.rs-2408790/v1.

留言 (0)

沒有登入
gif